# A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors

Source: https://onco.cc/trials/nct07498725/  
OnCo record `nct07498725` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of LRK-4189 escalation in advanced solid tumours, run by LARKSPUR BIOSCIENCES, INC., now recruiting.

## Summary

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07498725 by LARKSPUR BIOSCIENCES, INC., with 120 participants planned, started 2026-07-07 and due to reach its primary completion in 2029-06. Interventions recorded: LRK-4189 escalation, LRK-4189 expansion, LRK-4189 optimization and Chemo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07498725
- Phase: 1/2
- Setting: A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination With mFOLFOX6 or FOLFIRI in Patients With Solid Tumors
- Sponsor: LARKSPUR BIOSCIENCES, INC.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07498725: https://clinicaltrials.gov/study/NCT07498725

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07498725.json